Science Explorer Back to mapMap

Most cited papers from Ospedale San Luigi Gonzaga

What are the most cited papers from Ospedale San Luigi Gonzaga?

The most cited paper from Ospedale San Luigi Gonzaga is "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer" (Leena Gandhi et al., 2018), with 6,764 citations. Next come "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" (3,593) and "Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia" (3,508).

Showing 50 of 60 papers. Every paper with more than 309 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi et al. · New England Journal of Medicine Open access 16 Apr 2018 6,764
2 Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien et al. · New England Journal of Medicine Open access 12 Mar 2003 3,593
3 Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Brian J. Druker et al. · New England Journal of Medicine Open access 6 Dec 2006 3,508
4 Lung cancer: current therapies and new targeted treatments Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · The Lancet Open access 2 Sep 2016 3,404
5 International evidence-based recommendations for point-of-care lung ultrasound Giovanni Volpicelli et al. · Intensive Care Medicine Open access 5 Mar 2012 2,919
6 Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology Open access Sep 2016 2,650
7 COVID-19 pneumonia: different respiratory treatments for different phenotypes? Luciano Gattinoni, Davide Chiumello, Pietro Caironi et al. · Intensive Care Medicine Open access 14 Apr 2020 1,951
8 Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype Brunangelo Falini et al. · New England Journal of Medicine Open access 19 Jan 2005 1,923
9 Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine Open access 5 Jun 2010 1,691
10 Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program J Gäbert, Emmanuel Jean Beillard, Vincent H. J. van der Velden et al. · Leukemia 9 Oct 2003 1,540
11 Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis Ashley Harris Beecham et al. · Nature Genetics Open access193 authors 29 Sep 2013 1,466
12 Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel et al. · Journal of Clinical Oncology Open access 9 Mar 2020 1,181
13 Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM van Dongen, EA Macintyre, J Gäbert et al. · Leukemia Dec 1999 1,174
14 Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Heather A. Wakelee, Moïshe Liberman, Terufumi Kato et al. · New England Journal of Medicine Open access 3 Jun 2023 1,142
15 Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Martin Reck, Rolf Kaiser, Anders Mellemgaard et al. · The Lancet Oncology Open access 8 Jan 2014 962
16 MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome in cooperation with the Neuromyelitis Optica Study Group (NEMOS) et al. · Journal of Neuroinflammation Open access 28 Oct 2016 901
17 Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program Emmanuel Jean Beillard, Niels Pallisgaard, Vincent H. J. van der Velden et al. · Leukemia 9 Oct 2003 887
18 Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis Antonella Roetto, George V. Papanikolaou, Marianna Politou et al. · Nature Genetics 9 Dec 2002 866
19 Cardiovascular Events and Intensity of Treatment in Polycythemia Vera Roberto Marchioli et al. · New England Journal of Medicine Open access 8 Dec 2012 845
20 Oxidative Stress and Cell Signalling Giuseppe Poli, Gabriella Leonarduzzi, Fiorella Biasi et al. · Current Medicinal Chemistry May 2004 722
21 A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery Giancarlo Agnelli, Giorgio Bolis, Lorenzo Capussotti et al. · Annals of Surgery Open access 21 Dec 2005 695
22 The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies Giorgio V. Scagliotti, Nasser H. Hanna, Frank V. Fossella et al. · The Oncologist Open access 16 Feb 2009 694
23 Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia Giampaolo Bucaneve, Alessandra Micozzi, Francesco Menichetti et al. · New England Journal of Medicine Open access 7 Sep 2005 650
24 Pathogenesis of liver fibrosis: role of oxidative stress Giuseppe Poli · Molecular Aspects of Medicine Jun 2000 635
25 Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach Marco Volante, Paola Collini, Yuri E. Nikiforov et al. · The American Journal of Surgical Pathology 23 Jul 2007 624
26 Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa et al. · The Lancet Oncology Open access131 authors 4 Oct 2019 619
27 Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome Giovanni Volpicelli, Alessandro Mussa, Giorgio Garofalo et al. · The American Journal of Emergency Medicine 19 Sep 2006 615
28 Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Adrianus Johannes De Langen et al. · The Lancet Open access 7 Feb 2023 609
29 Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer Giorgio V. Scagliotti · JNCI Journal of the National Cancer Institute Open access 30 Sep 2003 603
30 Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology Wouter van Rheenen et al. · Nature Genetics Open access282 authors Dec 2021 579
31 Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study Franco Luigi Cavalot, Alessio Petrelli, Monica Traversa et al. · The Journal of Clinical Endocrinology & Metabolism Open access 7 Feb 2006 577
32 Myelin-oligodendrocyte glycoprotein antibody-associated disease Romain Marignier et al. · The Lancet Neurology Open access 18 Aug 2021 540
33 Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Talmadge E. King, Carlo Albera, Williamson Z. Bradford et al. · The Lancet Open access 30 Jun 2009 537
34 AME Position Statement on adrenal incidentaloma Massimo Terzolo, Antonio Stigliano, Iacopo Chiodini et al. · European Journal of Endocrinology Open access 7 Apr 2011 518
35 Breaking the neuronal sphere: regulation of the actin cytoskeleton in neuritogenesis Jorge Santos Da Silva, Carlos G. Dotti · Nature reviews. Neuroscience Review Sep 2002 479
36 Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti et al. · Annals of Neurology Open access 22 Jan 2021 464
37 Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Martin Faßnacht, Guillaume Assié, Eric Baudin et al. · Annals of Oncology Open access 27 Aug 2020 435
38 MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin in cooperation with the Neuromyelitis Optica Study Group (NEMOS) et al. · Journal of Neuroinflammation Open access 27 Oct 2016 434
39 The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials Giovanni Fucà et al. · British Journal of Cancer Open access 18 May 2020 397
40 Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Elias Joseph Jabbour, Hagop M. Kantarjian, Giuseppe Saglio et al. · Blood Open access 5 Dec 2013 396
41 How I do it: Lung ultrasound Luna Gargani, Giovanni Volpicelli · Cardiovascular Ultrasound Open access 3 Jul 2014 394
42 Efficacy and safety of once-weekly bortezomib in multiple myeloma patients Sara Bringhen et al. · Blood Open access 31 Aug 2010 383
43 T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β Luca Durelli, Laura Monteiro de Castro Conti, Marinella Clerico et al. · Annals of Neurology 20 Mar 2009 377
44 Glucocorticoid-induced osteoporosis: an update Gherardo Mazziotti, Alberto Angeli, John Paul Bilezikian et al. · Trends in Endocrinology and Metabolism Review May 2006 368
45 Endoscopic Combined Intrarenal Surgery in Galdakao-Modified Supine Valdivia Position: A New Standard for Percutaneous Nephrolithotomy? Cesare Marco Scoffone, Cecilia Maria Cracco, Marco Cossu et al. · European Urology 13 Aug 2008 368
46 Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update Marta del Campo, Brit Mollenhauer, Antonio Bertolotto et al. · Biomarkers in Medicine Aug 2012 361
47 Intravenous fluid therapy in the perioperative and critical care setting: Executive summary of the International Fluid Academy (IFA) Manu L. N. G. Malbrain, Thomas M Langer, Djillali Annane et al. · Annals of Intensive Care Open access 2020 335
48 Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Alfredo Berruti, Eric Baudin, Hans A. J. Gelderblom et al. · Annals of Oncology Open access 20 Sep 2012 332
49 Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial Luigi Dogliotti, Giacomo Cartenì, Salvatore Siena et al. · European Urology 2 Jan 2007 332
50 Adrenal Incidentaloma: A New Cause of the Metabolic Syndrome? Massimo Terzolo, Anna Rosa Pia, Anna Alı̀ et al. · The Journal of Clinical Endocrinology & Metabolism Mar 2002 327

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.